StreetAlpha.app
Home › Stocks › NRXP

NRX Pharmaceuticals, Inc. (NRXP)

$2.15
▼ −15.69%
LAST CLOSE · NOV 20

NRx Pharmaceuticals develops ketamine-based and other drugs for central nervous system disorders such as depression and PTSD. It last closed at $2.15 on Nov 20, down 15.69% on the day. The next earnings report for NRXP is expected around Mon, Feb 15, 2027. For the quarter ended Sep 2026, NRXP reported EPS of -$0.05 on revenue of $1.2M, with revenue up 378.9% from a year ago. Over its last 8 reports the stock moved an average of 5.8% the session after earnings.

AI Auto Pilots
Is NRXP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NRXP.

Key Stats

Last 12 months
Results
Revenue
$4.3M
+1681.4% vs a year ago
Net income
−$19.8M
−458.5% margin
EPS (diluted)
−$0.33
Gross margin
40.0%
$1.7M gross profit
Valuation
Market cap
$95.3M
44.3M shares
P/E
–
No P/E while losing money
Price to sales
22.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$19.8M
At Sep 30
Shareholder equity
−$2.0M
Shares outstanding
44.3M
At Nov 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $1.2M$1.2MFY2025

From NRXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Feb 15
Estimated date · Time not announced
Reported EPS
-$0.05
Quarter ended Sep 2026
Year ago EPS
-$0.27
Same quarter last year
Revenue
$1.2M
+378.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.77Dec '24Mar 2025: -$0.34Mar '25Jun 2025: -$0.98Jun '25Sep 2025: -$0.27Sep '25Dec 2025: $0.20Dec '25Mar 2026: -$0.04Mar '26Jun 2026: -$0.44Jun '26Sep 2026: -$0.05Sep '26Latest -$0.05
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $242,000Sep '25Dec 2025: $983,000Dec '25Mar 2026: $1.1MMar '26Jun 2026: $1.1MJun '26Sep 2026: $1.2MSep '26Latest $1.2M
How NRXP moved after its last 8 reports
Average move the session after a report ±5.8%
Aug 17, 2026Time not announced+4.9%
Aug 18, 2025After the close−9.2%
May 21, 2025After the close+2.3%
Mar 21, 2025After the close−0.5%
Nov 15, 2024After the close+9.2%
Aug 14, 2024After the close−6.5%
May 16, 2024Before the open+9.0%
Apr 2, 2024Time not announced−4.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NRXPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NRXP
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NRXP

Technical Analysis

NRXP · as of the Nov 20 close · updated each morning
Downtrend

The stock is 12% below its 20 day and 27% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 41). The nearest support is the swing low (Oct 30) at $2.11, and the nearest resistance the Pivot at $2.27.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 11.4%/day
Key levels
$5.0552 week high+134.9%
$3.18100 day average+47.9%
$2.99200 day average+39.1%
$2.7250 day average+26.5%
$2.50Swing high (Nov 11)+16.3%
$2.4120 day average+12.1%
$2.41Pivot R1+12.1%
$2.27Pivot+5.6%
$2.15Last close
$2.11Swing low (Oct 30)−1.9%
$2.01Pivot S1−6.5%
$1.6252 week low−24.7%
Indicators
RSI (14)41.44Middle of its rangeNeutral
MACD-0.09Above its signal lineBullish
Stochastic52.2Middle of its rangeNeutral
ADX (14)29.5Trending down
Williams %R-88.6Oversold below −80, overbought above −20Oversold
CCI (20)-66.3Oversold below −100, overbought above 100Neutral
Rate of change−9.7%Change over 10 sessionsBearish
ATR (14)$0.25Typical daily range, 11.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRXP

What happened before

See how NRXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NRXP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NRXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NRXPHow many large options trades hit NRXP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NRXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲37 buying vs 14 selling
  • ▲Held by funds +5.7 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5047+6.4%
In funds' top 10110.0%
Held by funds32.0%26.3%+5.7 pts
New / increased12 / 2518 / 16+8.8%
Reduced / sold out5 / 94 / 7+27.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NRXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NRXP Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 17, 2024Jonathan C JavittChairman and Chief ScientistBuy40,000$1.17$47K
Every insider buy and sale for NRXP over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NRXP insider trades →

From SEC Form 4 filings by NRXP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRXP is in one of them and how their past NRXP trades turned out.

NRXP in the AI portfolios
Loading…

NRXP News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NRXP in an article yet. Here's the latest on the wider market.

NRXP in the news

About NRX Pharmaceuticals

NRx Pharmaceuticals is a drug developer based in Wilmington, Delaware, focused on treatments for central nervous system disorders such as depression, post traumatic stress disorder, chronic pain and schizophrenia. Its lead product candidates are ketamine formulations, including a generic version called KETAFREE, and NRX-101, a combination of D-cycloserine and lurasidone, all still awaiting approval from the U.S. Food and Drug Administration. Through its majority owned subsidiary HOPE Therapeutics, the company also runs clinics in Florida that offer interventional psychiatry care to patients with treatment resistant depression and PTSD.

Headquarters
Wilmington, DE